Show simple item record

dc.contributor.authorMuselaers, CHJen_US
dc.contributor.authorBoers-Sonderen, MJen_US
dc.contributor.authorvan Oostenbrugge, TJen_US
dc.contributor.authorBoerman, OCen_US
dc.contributor.authorDesar, IMEen_US
dc.contributor.authorStillebroer, ABen_US
dc.contributor.authorMulder, SFen_US
dc.contributor.authorvan Herpen, CMLen_US
dc.contributor.authorLangenhuijsen, JFen_US
dc.contributor.authorOosterwijk, Een_US
dc.contributor.authorOyen, WJGen_US
dc.contributor.authorMulders, PFAen_US
dc.date.accessioned2017-04-03T11:22:54Z
dc.date.issued2016-05en_US
dc.identifier.citationEuropean urology, 2016, 69 (5), pp. 767 - 770en_US
dc.identifier.issn0302-2838en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/554
dc.identifier.eissn1873-7560en_US
dc.identifier.doi10.1016/j.eururo.2015.11.033en_US
dc.description.abstract<h4>Unlabelled</h4>Despite advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC), there is still an unmet need in the treatment of this disease. A phase 2 radioimmunotherapy (RIT) trial with lutetium 177 ((177)Lu)-girentuximab was initiated to evaluate the efficacy of this approach. In this nonrandomized single-arm trial, patients with progressive metastatic ccRCC who met the inclusion criteria received 2405 MBq/m(2) of (177)Lu-girentuximab intravenously. In the absence of persistent toxicity and progressive disease, patients were eligible for retreatment after 3 mo with 75% of the previous activity dose. A total of 14 patients were included. After the first therapeutic infusion, eight patients (57%) had stable disease (SD) and one (7%) had a partial regression. The treatment was generally well tolerated but resulted in grade 3-4 myelotoxicity in most patients. After the second cycle, continued SD was observed in five of six patients, but none were eligible for retreatment due to prolonged thrombocytopenia. In conclusion, RIT with (177)Lu-girentuximab resulted in disease stabilization in 9 of 14 patients with progressive metastatic ccRCC, but myelotoxicity prevented retreatment in some patients.<h4>Patient summary</h4>We investigated the efficacy of lutetium 177-girentuximab radioimmunotherapy in patients with metastatic kidney cancer. The treatment resulted in disease stabilization in 9 of 14 patients. The main toxicity was prolonged low blood cell counts.<h4>Trial registration</h4>ClinicalTrials.gov identifier: NCT02002312 (https://clinicaltrials.gov/ct2/show/NCT02002312).en_US
dc.formatPrint-Electronicen_US
dc.format.extent767 - 770en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectCarcinoma, Renal Cellen_US
dc.subjectKidney Neoplasmsen_US
dc.subjectThrombocytopeniaen_US
dc.subjectNeutropeniaen_US
dc.subjectLutetiumen_US
dc.subjectRadioisotopesen_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectRadioimmunotherapyen_US
dc.subjectRetreatmenten_US
dc.subjectNon-Randomized Controlled Trials as Topicen_US
dc.subjectCarbonic Anhydrase IXen_US
dc.subjectAntineoplastic Agents, Immunologicalen_US
dc.titlePhase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2015-11-27en_US
rioxxterms.versionofrecord10.1016/j.eururo.2015.11.033en_US
rioxxterms.licenseref.startdate2016-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEuropean urologyen_US
pubs.issue5en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.publication-statusPublisheden_US
pubs.volume69en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorOyen, Willemen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record